The 2018 Clinical Cancer Advances report of the American Society of Clinical Oncology has crowned an adoptive cell immunotherapy as its Advance of the Year. What is this innovative cancer treatment? What are the risks and benefits?
Research Round Up Podcast: Managing Side Effects, Breast Cancer, Chronic Myeloid Leukemia, and Myeloma
Cancer.Net Associate Editors discuss exciting new cancer research in the final Research Round Up podcast of the summer.
ASCO Annual Meeting 2017: Advances in Immunotherapy for Multiple Myeloma and Mesothelioma, and Targeted Therapies for Non-Small Cell Lung Cancer and HER2-Positive Breast Cancer
Oncology professionals from around the globe are in Chicago for the ASCO Annual Meeting. Today’s key research highlights include CAR T-cell therapy for multiple myeloma, immune checkpoint inhibitors for mesothelioma, and targeted therapy advances for non-small cell lung cancer and HER2-positive breast cancer.
Oncology professionals from around the world are in Chicago for the ASCO Annual Meeting. There, they will discuss the latest advances and newest thoughts in cancer research. Today’s highlights cover research that could potentially have the greatest impact to patient care for breast cancer, glioblastoma, neuroblastoma, and multiple myeloma.
From June 3 to June 7, oncology professionals from around the world will meet to discuss the latest in cancer research. If you can’t wait to learn about the latest research, check here for early highlights released in advance of the 2016 ASCO Annual Meeting.
This year, President Obama has focused attention on treatments and tools that help doctors tailor medical care for individual patients. Research presented at the 2015 ASCO Annual Meeting shows how targeted therapies can be used to improve the care of people with a number of different types of blood cancer.
In these two podcasts, Dr. Sundar Jagannath and Dr. Hope Rugo share the latest highlights in myeloma and breast cancer research.